Case Report

J Rheum Dis 2016; 23(5): 332-335

Published online October 31, 2016

© Korean College of Rheumatology

Serotonin Syndrome following Duloxetine Administration in a Fibromyalgia Patient: Case Report and Literature Review

Joon Sul Choi1, Ji Hyun Lee1, Suk Ki Park1, Beom Jin Shim1, Won Kyu Choi1, Sang Hyun Kim1, Seon Chool Hwang2

1Division of Rheumatology, Department of Internal Medicine, 2Department of Neurology, Maryknoll Medical Center, Busan, Korea

Correspondence to : Ji Hyun Lee, Division of Rheumatology, Department of Internal Medicine, Maryknoll Medical Center, 121 Junggu-ro, Jung-gu, Busan 48972, Korea. E-mail:ete@lycos.co.kr

Received: April 21, 2016; Revised: June 10, 2016; Accepted: June 29, 2016

This is a Free Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Serotonin syndrome, an adverse drug reaction, is a consequence of excess serotonergic agonism of central nervous system receptors and peripheral serotonergic receptors. Serotonin syndrome has been associated with large numbers of drugs and drug combinations, and serotonin-norepinephrine reuptake inhibitor-induced serotonin syndrome is rare. It is often described as a sign of excess serotonin ranging from tremor in mild cases to delirium, neuromuscular rigidity, and hyperthermia in life-threatening cases. Diagnosis is based on the symptoms and patient’s history, and several diagnostic criteria have been developed. We experienced a rare case of fibromyalgia accompanied by tremor, hyperreflexia, spontaneous clonus, muscle rigidity, and diaphoresis after 10 days of single use of duloxetine 30 mg. Only one case of serotonin syndrome resulting from administration of duloxetine has been reported in Korea, however that case resulted from co-administration of fluoxetine. We report here on this case along with a review of the relevant literature.

Keywords Serotonin syndrome, Fibromyalgia, Duloxetine

Article

Case Report

J Rheum Dis 2016; 23(5): 332-335

Published online October 31, 2016 https://doi.org/10.4078/jrd.2016.23.5.332

Copyright © Korean College of Rheumatology.

Serotonin Syndrome following Duloxetine Administration in a Fibromyalgia Patient: Case Report and Literature Review

Joon Sul Choi1, Ji Hyun Lee1, Suk Ki Park1, Beom Jin Shim1, Won Kyu Choi1, Sang Hyun Kim1, Seon Chool Hwang2

1Division of Rheumatology, Department of Internal Medicine, 2Department of Neurology, Maryknoll Medical Center, Busan, Korea

Correspondence to:Ji Hyun Lee, Division of Rheumatology, Department of Internal Medicine, Maryknoll Medical Center, 121 Junggu-ro, Jung-gu, Busan 48972, Korea. E-mail:ete@lycos.co.kr

Received: April 21, 2016; Revised: June 10, 2016; Accepted: June 29, 2016

This is a Free Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Serotonin syndrome, an adverse drug reaction, is a consequence of excess serotonergic agonism of central nervous system receptors and peripheral serotonergic receptors. Serotonin syndrome has been associated with large numbers of drugs and drug combinations, and serotonin-norepinephrine reuptake inhibitor-induced serotonin syndrome is rare. It is often described as a sign of excess serotonin ranging from tremor in mild cases to delirium, neuromuscular rigidity, and hyperthermia in life-threatening cases. Diagnosis is based on the symptoms and patient’s history, and several diagnostic criteria have been developed. We experienced a rare case of fibromyalgia accompanied by tremor, hyperreflexia, spontaneous clonus, muscle rigidity, and diaphoresis after 10 days of single use of duloxetine 30 mg. Only one case of serotonin syndrome resulting from administration of duloxetine has been reported in Korea, however that case resulted from co-administration of fluoxetine. We report here on this case along with a review of the relevant literature.

Keywords: Serotonin syndrome, Fibromyalgia, Duloxetine

JRD
Oct 01, 2024 Vol.31 No.4, pp. 191~263
COVER PICTURE
Ancestry-driven pathways for SLE-risk SNP-associated genes. The ancestry-driven key signaling pathways in Asians, Europeans, and African Americans were analyzed by enrichr (https://maayanlab.cloud/Enrichr/#libraries) using non-HLA SNP-associated genes. SLE: systemic lupus erythematosus, SNP: single-nucleotide polymorphism, JAK–STAT: janus kinase–signal transducers and activators of transcription, IFN: interferon gamma. (J Rheum Dis 2024;31:200-211)

Stats or Metrics

Share this article on

  • line

Related articles in JRD

Journal of Rheumatic Diseases

pISSN 2093-940X
eISSN 2233-4718
qr-code Download